Navitoclax-d8

SI-7917

Navitoclax-d8, >98% (HPLC)

CAS No. : [1217620-38-6]

Synonyms : ABT-263-d₈

IUPAC Name : (R)-4-(4-((4'-Chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-(morpholino-d8)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : Navitoclax‑d₈ is a deuterium‑labelled version of Navitoclax, which potently inhibits BCL‑xL, BCL‑2, and BCL‑w with K_ivalues below 1 nM. The labelled form is useful for pharmacokinetic, metabolic, and mechanistic studies involving BCL‑2 family inhibition.

References : Russak E. M. et al.: Ann. Pharmacother., 53(2), 211-216, 2019; Lock R. et al.: Pediatr. Blood Cancer, 50(6), 1181-1189, 2008; Wong M. et al.: Mol. Cancer Ther., 11(4), 1026-1035, 2012; Chen J. et al.: Mol. Cancer Ther., 10(12), 2340-9, 2011.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.